Cargando…
New-onset graves’ disease after the initiation of nivolumab therapy for gastric cancer: a case report
BACKGROUND: Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs) including thyroid dysfunction. There are only a few reports on Graves’ disease induced by ICIs. We report a case of new-onset Graves’ disease after the initiation of nivolumab therapy in a patient receiv...
Autores principales: | Yamada, Hiroshi, Okajima, Fumitaka, Onda, Takeshi, Fujimori, Shunji, Emoto, Naoya, Sugihara, Hitoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449083/ https://www.ncbi.nlm.nih.gov/pubmed/32847555 http://dx.doi.org/10.1186/s12902-020-00613-5 |
Ejemplares similares
-
Risk Preferences, Rationality of Choices, and Willingness to Pay for Preventive Medicine in Patients with Graves’ Thyrotoxicosis
por: Emoto, Naoya, et al.
Publicado: (2021) -
Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin
por: Okajima, Fumitaka, et al.
Publicado: (2017) -
Behavioral economics survey of patients with type 1 and type 2 diabetes
por: Emoto, Naoya, et al.
Publicado: (2015) -
A socioeconomic and behavioral survey of patients with difficult-to-control type 2 diabetes mellitus reveals an association between diabetic retinopathy and educational attainment
por: Emoto, Naoya, et al.
Publicado: (2016) -
Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal‐bolus insulin therapy: An open‐label, single‐center, parallel, randomized control study
por: Okajima, Fumitaka, et al.
Publicado: (2016)